Biblio
Found 12 results
Author Keyword Title Type [ Year
Filters: Author is Annamaria Ferrero [Clear All Filters]
“Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.”, Eur J Cancer, vol. 51, no. 3, pp. 352-8, 2015.
, “Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.”, Target Oncol, vol. 10, no. 4, pp. 583-96, 2015.
, “Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.”, Gynecol Oncol, vol. 136, no. 1, pp. 18-24, 2015.
, ,
“CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial.”, Br J Cancer, vol. 106, no. 4, p. 637, 2012.
, “Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.”, Ann Oncol, vol. 23, no. 5, pp. 1185-9, 2012.
, “EORTC Gynecological Cancer Group on the frontline of practice-changing clinical trials. ”, European Journal Cancer , vol. 10, no. 1, p. 73, 2012.
, “Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial.”, Ann Oncol, vol. 23, no. 8, p. 2027, 2012.
, “Development and validation of a nomogram to predict survival in CALYPSO and AGO-2.5 patients with platinum sensitive recurrent ovarian cancer. ”, Int J Gynecol Cancer , vol. 21, no. 12 Suppl 3, 2011.
, “Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.”, Br J Cancer, vol. 105, no. 8, pp. 1144-50, 2011.
, “Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.”, J Clin Oncol, vol. 28, no. 20, pp. 3323-9, 2010.
,